Kalinderi Kallirhoe, Papaliagkas Vasileios, Fidani Liana
a Department of General Biology , Medical School Aristotle University of Thessaloniki , Thessaloniki , Greece.
b Laboratory of Clinical Neurophysiology , Aristotle University of Thessaloniki AHEPA University Hospital , Thessaloniki , Greece.
Int J Neurosci. 2019 Apr;129(4):384-392. doi: 10.1080/00207454.2018.1538993. Epub 2018 Dec 2.
L-dopa remains the most effective symptomatic therapy for Parkinson's disease (PD) but unfortunately, its chronic use is often associated with motor complications. This review highlights the importance of pharmacogenetics in an individualised PD therapeutic approach.
review of the literature was done.
PD patients show remarkable heterogeneity in their response to L-dopa and this profound interindividual heterogeneity suggests that there is a genetic predisposition.
The impact of the genetic makeup of every individual on PD treatment appears to be of great importance in order to achieve not only the optimum therapeutic effect, but also with minimal side effects.
左旋多巴仍然是帕金森病（PD）最有效的对症治疗药物，但不幸的是，长期使用它常常会引发运动并发症。本综述强调了药物遗传学在个体化PD治疗方法中的重要性。
对文献进行了综述。
PD患者对左旋多巴的反应表现出显著的异质性，这种个体间的巨大异质性表明存在遗传易感性。
为了不仅实现最佳治疗效果，还能将副作用降至最低，每个人的基因组成对PD治疗的影响似乎至关重要。
